Antisense Pharma Receives FDA Orphan Drug Designation for Trabedersen

News   Oct 05, 2012

 
Antisense Pharma Receives FDA Orphan Drug Designation for Trabedersen
 
 
 
 

RELATED ARTICLES

Acquisition Sees Agilent Gain Powerful NGS IP Portfolio

News

Agilent Technologies announces its acquisition of the molecular and sample barcoding portfolios of Population Genetics Technologies.

READ MORE

Researchers Develop New Method to Generate Human Antibodies

News

Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.

READ MORE

Large-Scale Production of Living Brain Cells Enables Entirely New Research

News

After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE